Risk of Bleeding in Patients Undergoing Coronary Interventions on Dual and Triple Therapies: A Retrospective Study

By Staff Writer

July 20, 2023

Dual antiplatelet therapy, a combination of aspirin and clopidogrel, prasugrel or ticagrelor, is recommended for up to 12 months for secondary prevention of ischemic events among people undergoing coronary interventions. However, real-world bleeding among populations exposed to different dual antiplatelet therapy (DAPT) and triple therapy (TT) regimens has not been previously quantified. The economic impact of bleeding events is poorly characterised, particularly for minor bleeding, as is their impact on health-related quality of life.

A retrospective population-based cohort study sheds light on the bleeding risks associated with dual antiplatelet therapy and triple therapy (including an anticoagulant) in patients following coronary interventions.

Findings indicate that the incidence of bleeding was 5% in coronary artery bypass graft patients, 10% in conservatively managed acute coronary syndrome patients, and 9% in emergency percutaneous coronary intervention patients, compared to a significantly higher 18% in those on triple therapy.

Interestingly, dual antiplatelet therapy, compared to aspirin alone, increased the hazards of bleeding and major adverse cardiovascular events in coronary artery bypass grafting and conservatively managed acute coronary syndrome patients.

Moreover, among emergency percutaneous coronary intervention patients, dual antiplatelet therapy with ticagrelor (as opposed to clopidogrel) increased bleeding risks, but did not reduce major adverse cardiovascular events.

The study suggests that more potent dual antiplatelet therapy may increase bleeding risk without reducing major adverse cardiovascular events. These findings should be carefully considered by clinicians and decision-makers when recommending dual antiplatelet therapy.

There is still a need for prospective observational studies that provide high-quality data on outcomes and healthcare costs. A formal cost-effectiveness analysis could not be conducted due to the uncertainty surrounding the estimates for bleeding.

 

Reference url

Recent Posts

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

HPV testing HNSCC
    

HPV Testing in Head and Neck Squamous Cell Carcinoma

🔍 Are you up-to-date with the latest advancements in HPV testing for head and neck cancer?

Our comprehensive article looks into the innovation of diagnostic methods for HPV status determination in head and neck squamous cell carcinoma (HNSCC). From traditional p16 immunohistochemistry to innovative liquid biopsies, discover the critical role these advancements play in prognosis, treatment planning, and improving patient outcomes.

Look into this essential topic and see how these insights could revolutionize clinical practices.

#SyenzaNews #oncology #HealthTech #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.